Syndivia wins the 2017 European Venture Contest Final

Düsseldorf, Germany, December 12, 2017 -- Syndivia receives a winning award at the European Venture Contest Final as one of the top 20 companies, selected from over 1250+ applications and 600+ pitches held throughout the Tech Tour 2017. Official press-release: view online here

Syndivia is participating in the World ADC San Diego 2017

Meet us at the 8th World ADC San Diego on September 20-22, 2017, and learn about exciting new conjugation technologies offered by Syndivia.

Syndivia wins the France Tech Transfer Invest Award

PARIS, France, February 2, 2017 -- Syndivia wins the France Tech Transfer Invest Award during a Tech Tour event that took place in Paris on 1-2 February 2017. The event is a collaboration between the SATT, Tech Tour, Bpifrance and its EuroQuity platform and aims to efficiently and effectively support French tech companies to meet and engage with international investors and corporate partners.
For more information on the event visit: http://techtour.com/events/view.aspx?events_pages_id=7749

OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen

NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html

Syndivia receives the EU’s Horizon 2020 grant

The European Commission has named Syndivia as one of the new Phase 1 beneficiaries of the European Union's SME Instrument. SME Instrument is a highly competitive grant that supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument Phase 1 grant is aimed to fund the feasibility assessment of Syndivia's next-generation targeted cancer therapies.